Enzo Biochem (ENZB) AI Stock Analysis

• Market Cap: $35.68M
• Dividend Yield: N/A
• Average Volume (3M): 695.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 52,352,764
• 10 Day Avg. Volume: 73,703
• 30 Day Avg. Volume: 695,580
• PEG Ratio: -0.69
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: 0.06
• Enterprise Value/Revenue: 0.02
• Enterprise Value/Gross Profit: 0.16
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: $0.50
• Price Target Upside: -26.47% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: $0.50 ▼(-26.47%Downside)

Enzo Biochem's overall stock score is primarily impacted by its challenging financial performance and valuation issues due to declining revenues and profitability. However, the upcoming merger with Battery Ventures provides a positive outlook, offering a significant premium and a strategic path forward. Technical analysis shows potential short-term gains but also warns of overbought conditions.

Enzo Biochem Business Overview & Revenue Model

Company Description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

How the Company Makes Money

Enzo Biochem generates revenue primarily through its two operating segments. Enzo Clinical Labs earns money by providing diagnostic and clinical laboratory testing services to physicians, medical centers, and other healthcare providers. This includes routine blood tests, molecular diagnostics, and specialized testing services. Enzo Life Sciences generates revenue by selling a wide range of life sciences products, including reagents, assays, and kits to academic institutions, biopharmaceutical companies, and laboratories worldwide. The company also benefits from partnerships and licensing agreements that leverage its proprietary technologies and intellectual property, contributing to its earnings.

Enzo Biochem Financial Statement Overview

Summary

Enzo Biochem's financial performance is under pressure due to declining revenues and losses, as indicated by the income statement. The balance sheet shows moderate stability with low leverage, but the cash flow analysis highlights significant challenges with negative free cash flow and operating cash flow. Overall, the company is facing substantial financial hurdles, risking long-term sustainability without a turnaround.

Income Statement

Enzo Biochem's income statement reveals a challenging financial position with declining revenues and persistent losses. The company experienced a significant revenue drop from previous years, coupled with negative net income and EBIT margins in TTM (Trailing-Twelve-Months). The gross profit margin stands at 43.75%, indicating some cost management effectiveness, but the negative net profit margin of -76.75% highlights profitability issues.

Balance Sheet

The balance sheet shows moderate stability with a debt-to-equity ratio of 0.07, reflecting low leverage. However, the declining stockholders' equity and total assets suggest a shrinking balance sheet. The equity ratio of 68.34% indicates that a significant portion of assets is financed by equity, which is a positive sign of financial health.

Cash Flow

Cash flow analysis indicates significant challenges, with a negative free cash flow and operating cash flow in TTM. The company showed a negative free cash flow growth rate, reflecting cash generation issues. The operating cash flow to net income ratio is unfavorable, indicating that operations are not generating enough cash to cover losses.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	31.91M	31.06M	107.07M	117.73M	76.02M
Gross Profit	14.63M	11.57M	41.97M	53.58M	23.77M
EBITDA	-8.35M	-20.94M	-15.01M	3.35M	-27.59M
Net Income	-26.08M	20.29M	-22.58M	3.42M	-33.89M
Balance Sheet
Total Assets	85.76M	121.88M	95.86M	113.69M	112.54M
Cash, Cash Equivalents and Short-Term Investments	52.37M	82.37M	21.60M	43.50M	47.87M
Total Debt	3.51M	7.00M	20.59M	22.68M	32.79M
Total Liabilities	29.65M	43.42M	41.40M	45.10M	54.16M
Stockholders Equity	56.11M	78.46M	54.46M	68.59M	58.38M
Cash Flow
Free Cash Flow	-26.80M	-39.74M	-20.06M	-4.05M	-19.35M
Operating Cash Flow	-26.26M	-36.98M	-16.59M	387.00K	-17.18M
Investing Cash Flow	-545.00K	98.98M	25.22M	-34.50M	-2.17M
Financing Cash Flow	-4.19M	-1.13M	-241.00K	-242.00K	7.00M

Enzo Biochem Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZB, the sentiment is Positive. The current price of 0.68 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.62, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 68.22 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENZB.

Enzo Biochem Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TVRD	57 Neutral	$268.10M	―	-414.88%	―	-65.96%	40.80%
IGC	56 Neutral	$33.46M	―	-104.33%	―	-5.50%	56.57%
ENZB	54 Neutral	$35.68M	―	-13.95%	―	―	―
Sector *	52 Neutral	$7.62B	0.05	-63.03%	2.44%	16.33%	0.31%
ENLV	36 Underperform	$27.90M	―	-60.35%	―	―	53.95%
BCAB	35 Underperform	$23.36M	―	-246.21%	―	―	44.38%
NRSN	30 Underperform	$49.18M	―	-2880.11%	―	―	31.09%

Enzo Biochem Corporate Events

Enzo Biochem Announces Merger with Battery Ventures

On June 23, 2025, Enzo Biochem, Inc. entered into a merger agreement to be acquired by Battery Ventures for $0.70 per share in cash, totaling approximately $37 million. This transaction, which follows a strategic review by Enzo’s Board, represents a 75% premium to the company’s closing price on April 22, 2025. The merger is subject to customary closing conditions, including shareholder approval, and is expected to close in the third quarter of 2025. Upon completion, Enzo will become a privately held company, and its shares will no longer be publicly traded. The acquisition is seen as a strategic move to maximize shareholder value.